| 978- | SIL, | A comprehensive evaluation of the therapeutic potential of silibinin: a ray of hope in cancer treatment |
| - | Review, | NA, | NA |
| 4129- | Silicon, | Silica and aluminum in drinking water and cognitive impairment in the elderly |
| - | Study, | AD, | NA |
| 4125- | Silicon, | Oral silicon supplementation: an effective therapy for preventing oral aluminum absorption and retention in mammals |
| - | Review, | AD, | NA |
| 4123- | Silicon, | The potential influence of silica present in drinking water on Alzheimer's disease and associated disorders |
| - | Review, | AD, | NA |
| 4122- | Silicon, | Silicon-rich mineral water as a non-invasive test of the 'aluminum hypothesis' in Alzheimer's disease |
| - | Trial, | AD, | NA |
| 4126- | Silicon, | H2, | Oral Administration of Si-Based Agent Attenuates Oxidative Stress and Ischemia-Reperfusion Injury in a Rat Model: A Novel Hydrogen Administration Method |
| - | in-vivo, | NA, | NA |
| 4127- | Silicon, | Interference of Parenteral Nutrition Components in Silicon-Mediated Protection Against Aluminum Bioaccumulation |
| - | in-vivo, | AD, | NA |
| 4128- | Silicon, | Silicon as Versatile Player in Plant and Human Biology: Overlooked and Poorly Understood |
| - | Review, | NA, | NA |
| 4131- | Silicon, | Silicon reduces aluminum accumulation in rats: relevance to the aluminum hypothesis of Alzheimer disease |
| - | Study, | Nor, | NA |
| 4133- | Silicon, | Relation between aluminum concentrations in drinking water and Alzheimer's disease: an 8-year follow-up study |
| - | Study, | AD, | NA |
| 4134- | Silicon, | Garden Cress (Lepidium sativum) Seeds Ameliorated Aluminum-Induced Alzheimer Disease in Rats Through Antioxidant, Anti-Inflammatory, and Antiapoptotic Effects |
| - | in-vivo, | AD, | NA |
| 4136- | Silicon, | Aluminum Should Now Be Considered a Primary Etiological Factor in Alzheimer’s Disease |
| - | Review, | AD, | NA |
| 977- | SK, | A novel antiestrogen agent Shikonin inhibits estrogen-dependent gene transcription in human breast cancer cells |
| - | in-vitro, | BC, | T47D | - | in-vitro, | BC, | MDA-MB-231 | - | in-vitro, | BC, | MCF7 | - | in-vitro, | Nor, | HMEC |
| 965- | SK, | Shikonin suppresses proliferation and induces cell cycle arrest through the inhibition of hypoxia-inducible factor-1α signaling |
| - | in-vitro, | CRC, | HCT116 | - | in-vitro, | CRC, | SW-620 |
| 1050- | SK, | Shikonin improves the effectiveness of PD-1 blockade in colorectal cancer by enhancing immunogenicity via Hsp70 upregulation |
| - | in-vitro, | Colon, | CT26 |
| 1073- | SK, | Chemo, | Natural Compound Shikonin Is a Novel PAK1 Inhibitor and Enhances Efficacy of Chemotherapy against Pancreatic Cancer Cells |
| - | in-vitro, | PC, | PANC1 | - | in-vitro, | PC, | Bxpc-3 |
| 1049- | SK, | Shikonin inhibits immune checkpoint PD-L1 expression on macrophage in sepsis by modulating PKM2 |
| - | in-vivo, | NA, | NA |
| 5102- | SK, | GEM, | Shikonin suppresses tumor growth and synergizes with gemcitabine in a pancreatic cancer xenograft model: Involvement of NF-κB signaling pathway |
| 5103- | SK, | Attenuation of PI3K-Akt-mTOR Pathway to Reduce Cancer Stemness on Chemoresistant Lung Cancer Cells by Shikonin and Synergy with BEZ235 Inhibitor |
| - | in-vitro, | NSCLC, | A549 |
| 5101- | SK, | Shikonin induces colorectal carcinoma cells apoptosis and autophagy by targeting galectin-1/JNK signaling axis |
| - | vitro+vivo, | CRC, | SW-620 | - | vitro+vivo, | CRC, | HCT116 |
| 5100- | SK, | Shikonin-induced necroptosis in nasopharyngeal carcinoma cells via ROS overproduction and upregulation of RIPK1/RIPK3/MLKL expression |
| - | vitro+vivo, | NPC, | NA |
| 5104- | SK, | Shikonin induces cell cycle arrest in human gastric cancer (AGS) by early growth response 1 (Egr1)-mediated p21 gene expression. |
| - | in-vitro, | GC, | AGS |
| 2418- | SK, | Experimental Study of Hepatocellular Carcinoma Treatment by Shikonin Through Regulating PKM2 |
| - | in-vitro, | HCC, | SMMC-7721 cell | - | in-vitro, | HCC, | HUH7 | - | in-vitro, | HCC, | HepG2 |
| 2419- | SK, | Regulation of glycolysis and the Warburg effect in wound healing |
| - | in-vivo, | Nor, | NA |
| 2417- | SK, | Shikonin inhibits the Warburg effect, cell proliferation, invasion and migration by downregulating PFKFB2 expression in lung cancer |
| - | in-vitro, | Lung, | A549 | - | in-vitro, | Lung, | H446 |
| 2416- | SK, | Shikonin induces cell death by inhibiting glycolysis in human testicular cancer I-10 and seminoma TCAM-2 cells |
| - | in-vitro, | Testi, | TCAM-2 |
| 2361- | SK, | Natural shikonin and acetyl-shikonin improve intestinal microbial and protein composition to alleviate colitis-associated colorectal cancer |
| - | in-vivo, | CRC, | NA |
| 2415- | SK, | Shikonin induces programmed death of fibroblast synovial cells in rheumatoid arthritis by inhibiting energy pathways |
| - | in-vivo, | Arthritis, | NA |
| 2420- | SK, | Pyruvate kinase M2 regulates mitochondrial homeostasis in cisplatin-induced acute kidney injury |
| - | in-vivo, | AKI, | NA |
| 2360- | SK, | Shikonin inhibits growth, invasion and glycolysis of nasopharyngeal carcinoma cells through inactivating the phosphatidylinositol 3 kinase/AKT signal pathway |
| - | in-vitro, | NPC, | HONE1 | - | in-vitro, | NPC, | SUNE-1 |
| 2355- | SK, | Pharmacological properties and derivatives of shikonin-A review in recent years |
| - | Review, | Var, | NA |
| 2359- | SK, | Regulating lactate-related immunometabolism and EMT reversal for colorectal cancer liver metastases using shikonin targeted delivery |
| - | in-vivo, | Liver, | NA |
| 2356- | SK, | ESM1 enhances fatty acid synthesis and vascular mimicry in ovarian cancer by utilizing the PKM2-dependent warburg effect within the hypoxic tumor microenvironment |
| - | in-vitro, | Ovarian, | CaOV3 | - | in-vitro, | Ovarian, | OV90 | - | in-vivo, | NA, | NA |
| 2358- | SK, | SIRT1 improves lactate homeostasis in the brain to alleviate parkinsonism via deacetylation and inhibition of PKM2 |
| - | in-vivo, | Park, | NA |
| 2357- | SK, | GTPBP4 promotes hepatocellular carcinoma progression and metastasis via the PKM2 dependent glucose metabolism |
| - | Study, | HCC, | NA | - | in-vivo, | NA, | NA |
| 2370- | SK, | The role of pyruvate kinase M2 in anticancer therapeutic treatments |
| - | Review, | Var, | NA |
| 2354- | SK, | PKM2-dependent glycolysis promotes NLRP3 and AIM2 inflammasome activation |
| - | in-vivo, | Sepsis, | NA |
| 2364- | SK, | Pyruvate Kinase M2 Mediates Glycolysis Contributes to Psoriasis by Promoting Keratinocyte Proliferation |
| - | in-vivo, | PSA, | NA |
| 2362- | SK, | RIP1 and RIP3 contribute to shikonin-induced glycolysis suppression in glioma cells via increase of intracellular hydrogen peroxide |
| - | in-vitro, | GBM, | U87MG | - | in-vivo, | GBM, | NA | - | in-vitro, | GBM, | U251 |
| 2363- | SK, | Inhibition of PKM2 by shikonin impedes TGF-β1 expression by repressing histone lactylation to alleviate renal fibrosis |
| - | in-vivo, | CKD, | NA |
| 2470- | SK, | PKM2/PDK1 dual-targeted shikonin derivatives restore the sensitivity of EGFR-mutated NSCLC cells to gefitinib by remodeling glucose metabolism |
| - | in-vitro, | Lung, | H1299 |
| 2469- | SK, | Shikonin induces the apoptosis and pyroptosis of EGFR-T790M-mutant drug-resistant non-small cell lung cancer cells via the degradation of cyclooxygenase-2 |
| - | in-vitro, | Lung, | H1975 |
| 2230- | SK, | Shikonin induces ROS-based mitochondria-mediated apoptosis in colon cancer |
| - | in-vitro, | CRC, | HCT116 | - | in-vivo, | NA, | NA |
| 2231- | SK, | Shikonin Exerts Cytotoxic Effects in Human Colon Cancers by Inducing Apoptotic Cell Death via the Endoplasmic Reticulum and Mitochondria-Mediated Pathways |
| - | in-vitro, | CRC, | SNU-407 |
| 2232- | SK, | Shikonin Induces Autophagy and Apoptosis in Esophageal Cancer EC9706 Cells by Regulating the AMPK/mTOR/ULK Axis |
| - | in-vitro, | ESCC, | EC9706 |
| 2233- | SK, | Clinical trial on the effects of shikonin mixture on later stage lung cancer |
| - | Trial, | Lung, | NA |
| 2234- | SK, | Shikonin Suppresses Cell Tumorigenesis in Gastric Cancer Associated with the Inhibition of c-Myc and Yap-1 |
| - | in-vitro, | GC, | NA |
| 2213- | SK, | Shikonin attenuates cerebral ischemia/reperfusion injury via inhibiting NOD2/RIP2/NF-κB-mediated microglia polarization and neuroinflammation |
| - | in-vivo, | Stroke, | NA |
| 2191- | SK, | Shikonin Suppresses Skin Carcinogenesis via Inhibiting Cell Proliferation |
| - | in-vitro, | Melanoma, | NA |
| 2201- | SK, | Shikonin promotes ferroptosis in HaCaT cells through Nrf2 and alleviates imiquimod-induced psoriasis in mice |
| - | in-vitro, | PSA, | HaCaT | - | in-vivo, | NA, | NA |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:% Target#:% State#:% Dir#:%
wNotes=0 sortOrder:rid,rpid